clinical trial · NCT06121843
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company·phase1·recruiting·n = 147
Multiple MyelomaBMS-986393AlnuctamabMezigdomideIberdomideElranatamab
brief summary
The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants with relapsed and/or refractory multiple myeloma (RRMM).
started
Feb 22, 2024
primary completion
Aug 1, 2028
completion
Aug 1, 2028
last updated
Feb 18, 2026
official title
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol